Comparing Kyverna Therapeutics (NASDAQ:KYTX) and GSK (NYSE:GSK)

Kyverna Therapeutics (NASDAQ:KYTX) and GSK (NYSE:GSK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Volatility & Risk

Kyverna Therapeutics has a beta of 2.62, meaning that its share price is 162% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Insider and Institutional Ownership

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 22.0% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Kyverna Therapeutics and GSK, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1	0	4	0	2.60
GSK	3	6	1	0	1.80

Kyverna Therapeutics currently has a consensus price target of $28.67, indicating a potential upside of 216.41%. GSK has a consensus price target of $53.00, indicating a potential downside of 2.62%. Given Kyverna Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Kyverna Therapeutics is more favorable than GSK.

Valuation & Earnings

This table compares Kyverna Therapeutics and GSK”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31 million	($3.65)	-2.48
GSK	$43.07 billion	2.56	$7.54 billion	$3.70	14.71

GSK has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kyverna Therapeutics and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.47%	-66.70%
GSK	17.47%	46.75%	11.53%

Summary

GSK beats Kyverna Therapeutics on 7 of the 13 factors compared between the two stocks.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.